New drug shows promise for ulcerative colitis in early trial
NCT ID NCT07232576
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called SHR-1139 in 21 adults with moderate-to-severe ulcerative colitis, a condition that causes inflammation in the colon. The treatment has two parts: 12 weeks of induction therapy followed by 48 weeks of maintenance therapy. The main goal is to see if patients improve by week 12, with longer-term outcomes checked at week 60.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital,Sun Yat-Sen University
Guangzhou, Guangdong, 510080, China